Abstract Details

Title Incidence of Treatment-Emergent Adverse Events (TEAEs) According to Baseline Antiepileptic Drug (AED) Use: A Pooled Analysis of Data from Phase II/III Trials of Adjunctive Eslicarbazepine Acetate (ESL) in Children

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P5 - (-)

Poster/Presentation
Number 272

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Elaine C. Wirrell, MD, FAAN (Mayo Clinic/Dept of Child Neurology) PRESENTER	Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Wirrell has received publishing royalties from a publication relating to health care.
Tobias Loddenkemper, MD, FAAN	No disclosure on file
Joan A. Conry, MD (Children's National Medical Center)	No disclosure on file
Todd Grinnell, PhD	Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
David Cantu, PhD (Sunovion Pharmaceuticals Inc.)	Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Helena Gama	Helena Gama has received personal compensation for serving as an employee of Bial-Portela & Cª S.A..
Francisco Rocha	Francisco Rocha has received personal compensation for serving as an employee of BIAL - Portela.
	No disclosure on file
	No disclosure on file